Message #22 From:
NewsBot Date: December 11, 2005 09:30:00 PM
KAL News Web Alert: Callisto to Host Investor Conference Call Today to Discuss Developments in Anti-Cancer Drug Trials and IP Growth; Senior Management to Provide Progress Report on Recent Achievements During Call Scheduled to Start 12 p.m. Eastern
NEW YORK--(BUSINESS WIRE)--Dec. 12, 2005--Callisto Pharmaceuticals, Inc. (AMEX:KAL) (FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats, will host an investor conference call today at 12 p.m. Eastern to provide investors with a progress report on recent news, including achievements with respect to its intellectual property portfolio and in clinical trials of its anti-cancer drug candidates Atiprimod and L-Annamycin. The Company is developing the drugs as treatments for hematological cancers multiple myeloma and leukemia.
Dr. Gary Jacob, Callisto CEO, and Dr. Donald Picker, Executive Vice President, Research and Development, will provide the updates and answer investors' questions.
The conference call is scheduled to last approximately 30 minutes. To participate in the call by phone or listen on the web, follow the instructions below. The call will also be simultaneously webcast for listening via streaming audio.
WHAT: Callisto Pharmaceuticals' Investor Conference Call.
WHO: Dr. Gary S. Jacob, CEO and Chief Scientific Officer,
and Dr. Donald Picker, Executive Vice President,
Research and Development.
WHEN: Today, Dec. 12, at 12 p.m. Eastern.
HOW: To connect to the conference call in the United States,
please dial 888-428-4479. International callers can
dial 612-234-9959. When prompted, simply tell the
operator that you would like to connect to the "Callisto
Teleconference" call.
WEB: To listen to the call on the Web via streaming audio,
please visit
http://www.trilogy-capital.com/kal_conference.html
and follow the on-screen instructions.
COST: The conference call is free of charge.
ARCHIVE: The conference call will be archived for replay at
http://www.trilogy-capital.com/kal_conference.html.
About Callisto Pharmaceuticals, Inc.
Callisto is a biopharmaceutical company focused on the development of new drugs to treat various forms of cancer and other serious afflictions. Callisto's drug candidates in development currently include anti-cancer agents in clinical development, in addition to drugs for a range of other significant health care market segments, including biodefense. One of the Company's lead drug candidates, L-Annamycin, is being developed as a treatment for forms of relapsed leukemia, a currently incurable blood cancer. Callisto initiated a clinical trial of L-Annamycin in adult relapsed acute lymphocytic leukemia patients in 4Q 2005. L-Annamycin, a new compound from the anthracycline family of proven anti-cancer drugs, has a novel therapeutic profile, including activity against resistant diseases and significantly reduced cardiotoxicity, or damage to the heart, compared to currently available drug alternatives. Another anti-cancer drug, Atiprimod, is in development to treat relapsed multiple myeloma, a blood cancer. Atiprimod has entered Phase I/IIa human clinical trials in relapsed multiple myeloma patients. Callisto also has drugs in preclinical development for gastro-intestinal inflammation, and a program focused on the development of a drug to protect against Staphylococcus and Streptococcus biowarfare agents. Callisto has exclusive worldwide licenses from AnorMED Inc. and M.D. Anderson Cancer Center to develop, manufacture, use and sell Atiprimod and L-Annamycin, respectively. For investor-specific information about Callisto, including recent news and stock price data, please visit http://www.trilogy-capital.com/tcp/callisto/. For an Investor Fact Sheet about Callisto, please visit http://www.trilogy-capital.com/tcp/callisto/factsheet.html. To view an informational presentation of the Company's development pipeline of drug candidates, visit http://www.trilogy-capital.com/tcp/callisto/powerpoint.html. Callisto is also listed on the Frankfurt Stock Exchange under the ticker symbol CA4. For additional information, visit www.callistopharma.com.
Forward-Looking Statements
Certain statements made in this press release are forward-looking. Such statements are indicated by words such as "expect," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Callisto believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the Callisto Pharmaceuticals Annual Report on Form 10-K/A for the year ended December 31, 2004, and other periodic reports, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that products that appeared promising in early clinical trials do not demonstrate efficacy in larger-scale clinical trials, the risk that Callisto will not obtain approval to market its products, the risks associated with dependence upon key personnel and the need for additional financing.
